Diagnostic Imaging October 17, 2024
When employing a PI-RADS > 4 cutoff, researchers found that the mdprostate software provided an 85.5 percent sensitivity rate for diagnosing clinically significant prostate cancer on mpMRI.
Emerging research suggests an artificial intelligence (AI) platform may improve prostate cancer (PCa) detection on multiparametric magnetic resonance imaging (mpMRI).
In a retrospective study, recently published in the European Journal of Radiology, researchers evaluated the AI-enabled mdprostate software (Mediaire) in 123 men (mean age of 66.8 years) who had mpMRI and subsequent biopsies. Fifty-five men in the cohort had clinically significant prostate cancer (csPCa), 53 participants had no PCa and 15 patients had non-significant PCa, according to the study.
The researchers found that the AI software had a 100 percent sensitivity rate and...
Today's Sponsors
Today's Sponsor